In short
Avenciguat, also known as BI 685509, is an investigational drug being studied in clinical trials for various conditions, including diabetic kidney disease, liver cirrhosis with portal hypertension, and systemic sclerosis. These trials aim to evaluate the safety, tolerability, and efficacy of Avenciguat in treating these complex medical conditions.
At a glance
- Drug Name
- Avenciguat (BI 685509)
- Conditions Studied
- Diabetic kidney disease, Liver cirrhosis with portal hypertension, Systemic sclerosis
- Administration
- Oral tablets, varying from once daily to three times a day
- Primary Objectives
- Safety, tolerability, pharmacokinetics, efficacy in treating targeted conditions
- Key Outcome Measures
- UACR, HVPG, FVC, mRSS, adverse events
- Trial Durations
- Varying from a few months to over a year
- Study Designs
- Randomized, placebo-controlled, double-blind, parallel group
- Patient Populations
- Adults with specific conditions, healthy volunteers for some studies
What is BI 685509?
BI 685509, also known as Avenciguat, is a new drug being developed to treat various medical conditions. It is currently undergoing clinical trials to evaluate its safety and effectiveness in treating different diseases. Researchers are studying how the body processes this medication and how it might benefit patients with specific health issues.
Medical Conditions Treated
BI 685509 is being investigated for several medical conditions, including:
- Portal Hypertension: This is a condition where there is high blood pressure in the main blood vessel (portal vein) that carries blood from the intestines to the liver. BI 685509 is being studied to see if it can help reduce this pressure in patients with liver cirrhosis.
- Systemic Sclerosis (Scleroderma): This is a rare autoimmune disease that causes hardening and tightening of the skin and connective tissues. BI 685509 is being tested to see if it can improve lung function and other symptoms in people with this condition.
- Diabetic Kidney Disease: This is a complication of diabetes that affects the kidneys. Researchers are investigating whether BI 685509 can improve kidney function in patients with this condition.
How BI 685509 Works
While the exact mechanism of action is not fully explained in the provided information, BI 685509 appears to have effects on blood vessels and potentially on organ function. In portal hypertension, for example, it may help to reduce the pressure in blood vessels leading to the liver. In systemic sclerosis, it might improve blood flow and reduce fibrosis (scarring) in various organs, particularly the lungs.
Clinical Trials
BI 685509 is currently being studied in several clinical trials:
- Some trials are testing the safety and how the body processes the drug in healthy volunteers.
- Other studies are investigating its effects in patients with specific conditions, such as liver cirrhosis with portal hypertension, systemic sclerosis, and diabetic kidney disease.
- Researchers are also looking at how food and other medications might affect how BI 685509 works in the body.
Administration and Dosage
BI 685509 is typically administered as tablets that are taken orally (by mouth). The dosage and frequency of administration may vary depending on the condition being treated and the specific clinical trial:
- In some studies, it is taken twice daily.
- In others, it may be taken three times a day.
- The exact dosage is still being determined through clinical trials.
Potential Side Effects
As BI 685509 is still in the research phase, all potential side effects may not be known. However, researchers are closely monitoring for any adverse effects during clinical trials. Some areas of focus include:
- Effects on blood pressure, including the possibility of low blood pressure (hypotension).
- Any signs of liver or kidney problems.
- Other general health effects that may occur during treatment.
Ongoing Research
Research on BI 685509 is ongoing, with several clinical trials in different phases. These studies aim to:
- Determine the most effective and safe dosages for different conditions.
- Evaluate how well the drug works compared to placebo or existing treatments.
- Assess long-term safety and effectiveness.
- Understand how the drug interacts with food and other medications.
As research progresses, more information about BI 685509's effectiveness, safety profile, and potential uses will become available. Patients interested in this medication should discuss with their healthcare providers about the possibility of participating in clinical trials or when the drug might become available for general use.